Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Spark Therapeutics
Spark Therapeutics
Spark licenses blindness gene therapy rights outside U.S. to Novartis
Yahoo/Reuters
Thu, 01/25/18 - 12:00 am
Spark Therapeutics
Novartis
Luxturna
gene therapy
Three Interviews From the J.P. Morgan Healthcare Conference
Motley Fool
Mon, 01/15/18 - 06:37 pm
JPMHC 2018
Alnylam
Arena Pharmaceuticals
Spark Therapeutics
Drugmakers see a pricing blueprint in an $850,000 gene therapy
Reuters
Fri, 01/12/18 - 06:30 pm
gene therapy
drug pricing
Spark Therapeutics
Luxturna
Spark prices its gene therapy as most expensive U.S. medicine — but with plans to ease cost concerns
Stat
Wed, 01/3/18 - 11:09 am
Spark Therapeutics
gene therapy
Luxturna
drug pricing
rebates
FDA rolls out an early and historic OK for Spark’s pioneering gene therapy
Endpoints
Tue, 12/19/17 - 11:06 am
FDA
Spark Therapeutics
gene therapy
Luxturna
retinal dystrophies
8 Takeout targets to watch in 2018
BioPharma Dive
Sat, 12/16/17 - 08:41 am
M&A
Allergan
Alnylam
Biomarin
Bristol-Myers Squibb
Incyte
Madrigal Pharmaceuticals
Spark Therapeutics
Sucampo
[video]ASH 2017 Recap: These Were the Big Winners and Losers
Motley Fool
Sat, 12/16/17 - 08:39 am
ASH2017
Bluebird Bio
Juno Therapeutics
Spark Therapeutics
Biomarin
JNJ
Celgene
ASH 2017: What you missed
BioPharma Dive
Wed, 12/13/17 - 06:35 pm
ASH17
Biomarin
Spark Therapeutics
Gilead Sciences
Novartis
Juno Therapeutics
AbbVie
Roche
JNJ
ASH17: Spark gene therapy falls behind BioMarin in hemophilia
BioPharma Dive
Tue, 12/12/17 - 10:50 pm
ASH17
Spark Therapeutics
gene therapy
Biomarin
hemophilia A
SPK-8011
Spark, Pfizer pass another milestone with impressive results treating hemophilia B
Endpoints
Thu, 12/7/17 - 09:14 am
Spark Therapeutics
Pfizer
hemophilia B
SPK-9001
How much is your vision worth? Spark CEO Jeff Marrazzo has a price in mind
Endpoints
Wed, 11/8/17 - 09:21 am
Spark Therapeutics
Jeff Marrazzo
gene therapy
RPE65-mediated retinal dystrophy
drug pricing
9 Notable Biotechs Presenting At This Year's ASH Meeting
Yahoo
Tue, 11/7/17 - 09:56 am
ASH
Bluebird Bio
LentiGlobin
Ziopharm Oncology
Bellicum
BPX-501
Spark Therapeutics
SPK-8011
Biomarin
BMN 270
Juno Therapeutics
CAR-T
Novartis
Geron
imetelstat
Immunogen
IMGN632
IMGN779
Reader poll: Pfizer most likely buyer for Spark
Biopharma Dive
Wed, 10/25/17 - 10:39 pm
Pfizer
Spark Therapeutics
M&A
We may soon have our first $1 million drug. Who will pay for it? And how?
Stat
Sat, 10/14/17 - 11:04 am
gene therapy
drug pricing
Spark Therapeutics
Luxturna
Spark’s Gene Therapy to Restore Vision Wins Unanimous FDA Panel Vote
Xconomy
Thu, 10/12/17 - 10:22 pm
Spark Therapeutics
gene therapy
FDA
advisory panels
Luxturna
Here Come More Gene Therapies -- And More Pricing Debates
Forbes
Wed, 10/11/17 - 10:03 am
gene therapies
drug pricing
Luxturna
Spark Therapeutics
Kymriah
Novartis
FDA To Advisors: What If One-Time Gene Therapy Needs Extra Doses?
Xconomy
Tue, 10/10/17 - 11:26 pm
FDA
gene therapy
Spark Therapeutics
Spark Therapeutics faces a grilling as FDA ponders a pioneering OK for gene therapy
Endpoints
Tue, 10/10/17 - 09:38 am
Spark Therapeutics
FDA
gene therapy
Luxturna
retinal dystrophies
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
Stat
Tue, 10/3/17 - 11:50 am
biotech
Axovant Sciences
intepirdine
SAGE Therapeutics
brexanolone
AbbVie
risankizumab
Global Blood Therapeutics
GBT-440
DBV Technologies
Viaskin Peanut
Cytokinetics
Amicus Therapeutics
ATB200
Spark Therapeutics
Bluebird Bio
Revance Therapeutics
RT002
Spark offers a glimpse of efficacy in first two hemophilia A gene therapy patients
Endpoints
Wed, 08/2/17 - 09:39 am
Spark Therapeutics
hemophilia A
gene therapy
SPK-8011
Pages
« first
‹ previous
1
2
3
4
5
6
next ›
last »